Newcastle Disease Virus-Like Particles Displaying Prefusion-Stabilized SARS-CoV-2 Spikes Elicit Potent Neutralizing Responses
The COVID-19 pandemic highlights an urgent need for vaccines that confer protection from SARS-CoV-2 infection. One approach to an effective COVID-19 vaccine may be through the display of SARS-CoV-2 spikes on the surface of virus-like particles, in a manner structurally mimicking spikes on a native v...
Main Authors: | Yongping Yang, Wei Shi, Olubukola M. Abiona, Alexandra Nazzari, Adam S. Olia, Li Ou, Emily Phung, Tyler Stephens, Yaroslav Tsybovsky, Raffaello Verardi, Shuishu Wang, Anne Werner, Christina Yap, David Ambrozak, Tatsiana Bylund, Tracy Liu, Richard Nguyen, Lingshu Wang, Baoshan Zhang, Tongqing Zhou, Gwo-Yu Chuang, Barney S. Graham, John R. Mascola, Kizzmekia S. Corbett, Peter D. Kwong |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-01-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/2/73 |
Similar Items
-
Surface-modified measles vaccines encoding oligomeric, prefusion-stabilized SARS-CoV-2 spike glycoproteins boost neutralizing antibody responses to Omicron and historical variants, independent of measles seropositivity
by: Miguel Á. Muñoz-Alía, et al.
Published: (2024-02-01) -
Stabilisation of Viral Membrane Fusion Proteins in Prefusion Conformation by Structure-Based Design for Structure Determination and Vaccine Development
by: Henriette Ebel, et al.
Published: (2022-08-01) -
Enhancing Anti-G Antibody Induction by a Live Single-Cycle Prefusion F—Expressing RSV Vaccine Improves In Vitro and In Vivo Efficacy
by: Pramila Lamichhane, et al.
Published: (2022-11-01) -
A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults
by: Antonios O. Aliprantis, et al.
Published: (2021-05-01) -
Prefusion RSV F Immunization Elicits Th2-Mediated Lung Pathology in Mice When Formulated With a Th2 (but Not a Th1/Th2-Balanced) Adjuvant Despite Complete Viral Protection
by: Katherine M. Eichinger, et al.
Published: (2020-07-01)